Telix Pharmaceuticals Ltd. TLX 深 滬
已收盤 10-31 16:00:00 美东时间
10.66
-0.070
-0.65%
華盛通- 最 高10.71
- 今 開10.66
- 成交量 5.90万股
- 最 低 10.54
- 昨 收 10.73
- 總市值 35.71亿
- 52周最高 30.36
- 市盈率 靜 111.74
- 換手率 0.02%
- 52周最低 8.93
- 委 比 23.55%
- 總股本 3.35亿
- 歷史最高 30.36
- 量 比 0.81
- 振 幅 1.58%
- 歷史最低 8.93
- 每 手 1
- 風險率 2.95%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Telix Pharmaceuticals to Release Shares from Voluntary Escrow
An announcement from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Teli...
10-29 06:18
TLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging
Melbourne, Australia and Indianapolis – Telix Pharmaceuticals announced that updated guidelines from leading nuclear medicine societies now include its investigational PET agent, TLX250-CDx, for imaging renal masses. The expert panel highlighted TLX250-CDx as a non-invasive, accurate method for diagnosing clear cell renal cell carcinoma (ccRCC), referencing data from the successful Phase 3 ZIRCON trial. The inclusion marks a significant step towa...
10-23 11:00
Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
Telix Pharmaceuticals has initiated a Phase 1 clinical trial for TLX090, a radiopharmaceutical targeting bone metastases-related pain. Designed to deliver targeted radiation, TLX090 aims to minimize damage to healthy tissues while providing long-lasting pain relief. The SOLACE trial, enroll up to 33 patients, evaluates safety, efficacy, and pharmacokinetics. Existing treatments like opioids and EBRT have significant limitations, making TLX090's n...
10-22 20:00
Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance
Telix Pharmaceuticals posts 53% Q3 revenue growth to $206 million, lifts FY25 guidance to up to $820 million amid strong PSMA imaging and reimbursement gains.
10-15 02:11
Telix Pharmaceuticals boosts FY25 guidance after strong Q3
Telix Pharmaceuticals (OTCPK:TLPPF) reported Q3 2025 revenue of $206M, up 53% year-over-year. FY 2025 revenue guidance raised to $800–$820 million, up from prior forecasts. R&D spending to rise 20–25%...
10-14 15:51
Telix Pharmaceuticals Sees Q3 Sales $206.000M
Telix Pharmaceuticals (NASDAQ:TLX) sees Q3 sales of $206.000 million.
10-14 15:21
Telix Pharmaceuticals Raises FY2025 Sales Guidance from $770.000M-$800.000M to $800.000M-$820.000M
Telix Pharmaceuticals (NASDAQ:TLX) raises FY2025 sales outlook from $770.000 million-$800.000 million to $800.000 million-$820.000 million.
10-14 15:21
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
Telix Pharmaceuticals reported unaudited Q3 2025 revenue of $206 million, up 53% year-over-year. Key highlights include full reimbursement for Gozellix in the U.S., Illuccix approvals in 19 European markets and the UK, and the start of BiPASS™ trial for prostate cancer diagnosis. Clinical trial progress includes first patients dosed in ProstACT and TLX400 studies. Manufacturing facilities in Australia and Japan received radiation licenses. FY 202...
10-14 06:22
Telix Pharmaceuticals Announces Cessation of Securities
Telix Pharmaceuticals ( ($AU:TLX) ) just unveiled an update. Telix Pharmaceutic...
10-10 06:39
Telix Pharmaceuticals Expands ASX Quotation with New Securities
Telix Pharmaceuticals ( ($AU:TLX) ) has issued an update. Telix Pharmaceuticals...
10-10 06:28
